My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.63 -0.53 (-1.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

2 Biotech Stocks to Buy Hand Over Fist in March ↗

March 08, 2024

These stocks are worth buying in most months of the year.

Via The Motley Fool

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success ↗

March 06, 2024

With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

March 05, 2024

EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 02, 2024

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

Via The Motley Fool

Topics Stocks

2 Stocks Under $30 to Buy and Hold ↗

February 19, 2024

You don't need to be a millionaire to get started. Investing on a budget can work, too.

Via The Motley Fool

Recap: Exelixis Q4 Earnings ↗

February 06, 2024

Via Benzinga

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

Earnings Preview For Exelixis ↗

February 05, 2024

Via Benzinga

Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying ↗

February 23, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

The 3 Best Biotech Stocks to Buy in February 2024 ↗

February 13, 2024

The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

February 13, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

February 10, 2024

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

Via The Motley Fool

Topics Stocks

3 Attractive Medical Stocks To Buy After Earnings ↗

February 08, 2024

Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare...

Via Talk Markets

In the world of growth stocks, NASDAQ:EXEL shines as a value proposition. ↗

February 05, 2024

NASDAQ:EXEL, a growth stock which is not overvalued.

Via Chartmill

Breaking Down Exelixis: 7 Analysts Share Their Views ↗

January 30, 2024

Via Benzinga

NASDAQ:EXEL is showing good growth, while it is not too expensive. ↗

December 21, 2023

Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Exelixis (EXEL) Q4 2023 Earnings Call Transcript ↗

February 06, 2024

EXEL earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study ↗

January 23, 2024

Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 ↗

January 21, 2024

These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.

Via InvestorPlace

3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗

January 18, 2024

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

Via InvestorPlace

6 Analysts Have This to Say About Exelixis ↗

December 13, 2023

Via Benzinga

NASDAQ:EXEL, a growth stock which is not overvalued. ↗

November 29, 2023

Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.

Via Chartmill

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell' ↗

January 12, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified

Via Benzinga

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

January 11, 2024

Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced.

Via Chartmill

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? ↗

January 08, 2024

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an

Via Benzinga

Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes ↗

January 08, 2024

Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.

Via Investor's Business Daily

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.